NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $3.03 -0.11 (-3.50 %) (As of 07/17/2018 01:38 AM ET)Previous Close$3.14Today's Range$3.00 - $3.2852-Week Range$2.58 - $5.66Volume902,500 shsAverage Volume1.59 million shsMarket Capitalization$434.39 millionP/E Ratio-4.92Dividend YieldN/ABeta0.87 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut. Receive ACHN News and Ratings via Email Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:ACHN CUSIP00448Q20 Webwww.achillion.com Phone203-624-7000 Debt Debt-to-Equity RatioN/A Current Ratio38.07 Quick Ratio38.07 Price-To-Earnings Trailing P/E Ratio-4.92 Forward P/E Ratio-5.41 P/E GrowthN/A Sales & Book Value Annual Sales$15 million Price / Sales27.94 Cash FlowN/A Price / CashN/A Book Value$2.35 per share Price / Book1.29 Profitability EPS (Most Recent Fiscal Year)($0.62) Net Income$-85,230,000.00 Net MarginsN/A Return on Equity-25.57% Return on Assets-24.65% Miscellaneous Employees88 Outstanding Shares138,340,000Market Cap$434.39 Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions What is Achillion Pharmaceuticals' stock symbol? Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN." How were Achillion Pharmaceuticals' earnings last quarter? Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.01. View Achillion Pharmaceuticals' Earnings History. When is Achillion Pharmaceuticals' next earnings date? Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Achillion Pharmaceuticals. What price target have analysts set for ACHN? 7 brokerages have issued 1 year price objectives for Achillion Pharmaceuticals' stock. Their forecasts range from $3.50 to $7.00. On average, they anticipate Achillion Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 65.0% from the stock's current price. View Analyst Ratings for Achillion Pharmaceuticals. What is the consensus analysts' recommendation for Achillion Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Achillion Pharmaceuticals' key competitors? Some companies that are related to Achillion Pharmaceuticals include Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), Biohaven Pharmaceutical (BHVN), ARMO Biosciences (ARMO), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Uniqure (QURE), TherapeuticsMD (TXMD), Theravance Biopharma (TBPH), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX) and G1 Therapeutics (GTHX). Who are Achillion Pharmaceuticals' key executives? Achillion Pharmaceuticals' management team includes the folowing people: Dr. Milind S. Deshpande, CEO & Director (Age 61)Mr. Joseph Truitt, Pres & COO (Age 53)Ms. Mary Kay Fenton, Exec. VP, CFO & Principal Accounting Officer (Age 54)Glenn Schulman, Exec. Director of Investor RelationsMs. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63) Has Achillion Pharmaceuticals been receiving favorable news coverage? News articles about ACHN stock have trended somewhat negative recently, Accern reports. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of -0.06 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.53 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. How do I buy shares of Achillion Pharmaceuticals? Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Achillion Pharmaceuticals' stock price today? One share of ACHN stock can currently be purchased for approximately $3.03. How big of a company is Achillion Pharmaceuticals? Achillion Pharmaceuticals has a market capitalization of $434.39 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe. How can I contact Achillion Pharmaceuticals? Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000. MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 399 (Vote Outperform)Underperform Votes: 298 (Vote Underperform)Total Votes: 697MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?